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Abstract 
Background: 3-Nitro-4-hydroxy phenyl arsenic acid, roxarsone, is widely used as an organic arsenic feed additive for 
livestock and poultry, which may increase the level of arsenic in the environment and the risk of exposure to arsenic in 
human. Little information is focused on the angiogenesis roxarsone-induced and its mechanism at present. This paper 
aims to study the role of PI3K/Akt signaling in roxarsone-induced angiogenesis in rat vascular endothelial cells and a 
mouse B16–F10 melanoma xenograft model.
Results: The results showed that treatment with 0.1–10.0 µmol/L roxarsone resulted in an increase in the OD rate 
in the MTT assay, the number of BrdU-positive cells in the proliferation assay, the migration distance in the scratch 
test and the number of meshes in tube formation assay. Further, treatment with 1.0 µmol/L roxarsone was associated 
with significantly higher phosphorylation of PI3K/Akt and expression of VEGF than the control treatment. The PI3K 
inhibitor was found to significantly combat the effects of 1.0 µmol/L roxarsone. Furthermore, roxarsone treatment was 
observed to increase the weight and volume of B16–F10 xenografts and VEGF expression and PI3K/Akt phosphoryla-
tion in a dose-dependent manner, with the 25 mg/kg dose having significant effects.
Conclusions: These results demonstrate that roxarsone has the ability to promote growth and tube formation in 
vascular endothelial cells and the growth of mouse B16–F10 xenografts. Further, the findings also indicate that  
PI3K/Akt signaling plays a regulatory role in roxarsone-induced angiogenesis in vivo and in vitro.
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Background
3-Nitro-4-hydroxy phenyl arsenic acid, also known as 
roxarsone, is widely used as an organic arsenic feed addi-
tive for livestock and poultry. Only a small amount of 
roxarsone that in ingested in animals is absorbed by 
the body, which means that the vast majority of roxar-
sone is excreted via the feces [1, 2]. Thus, the use of ani-
mal manure as an organic fertilizer is associated with an 
increase in the level of arsenic in the environment and a 
subsequent increase in the risk of arsenic exposure in 
humans [3, 4]. There is a high correlation between the 
level of arsenic in environment and the risk of human 
cancers including skin, bladder, lung, and liver cancers [5].
Arsenic has been identified as a type II carcinogen by 
the International Agency for Research on Cancer [6]. On 
the other hand, certain arsenic compounds have been 
approved by the Food and Drug Administration for the 
treatment of some blood cancers such as acute promye-
locytic leukemia and their efficacy has been evaluated in 
clinical trials of the treatment of multiple myelomas and 
a variety of solid tumors [7]. Arsenic is known to have 
a biphasic impact on angiogenesis: that is, it promotes 
angiogenesis at low levels and inhibits angiogenesis at 
high levels. This may explain the controversial biological 
effects of arsenic on cancers. For example, Nicole et  al. 
[8] suggested that the levels used clinically to treat leu-
kemia may not be suitable for treating solid tumors, since 
the therapeutic levels for leukemia may enhance solid 
tumor growth instead of limiting it.
Roxarsone is widely used as a growth promoter to 
improve weight gain, feed efficiency and pigmentation 
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in chicken and pigs. The mechanism by which roxar-
sone increases productivity is not yet clear, but increased 
blood supply (venous stasis) is recognized as a factor that 
promotes coloration [9]. Basu et  al. [10] reported that 
low concentrations of roxarsone had a higher angiogenic 
index than AsIII in human aortic endothelial cells and 
lung microvascular endothelial cells. Their results also 
indicated that roxarsone and AsIII promote the angio-
genic phenotype in human endothelial cells through their 
distinct effects on signaling mechanisms. Our previous 
studies have also demonstrated the potential of roxar-
sone to promote angiogenesis in vitro in rat endothelial 
cells and ex vivo in rat aortic rings [11, 12]. Angiogene-
sis plays a pivotal role in the initiation of carcinogenesis 
and tumor progression, vascular diseases and various 
ischemic and inflammatory diseases [13–16]. The pro-
angiogenic effect of roxarsone may explain why arsenic 
exposure is closely associated with the development of 
many cancers [17].
Phosphatidylinositol-3-kinase (PI3K) is located at the 
cell membrane; when it is activated by a number of recep-
tor tyrosine kinases, it initiates the signaling cascade via 
phosphorylation of phosphatidylinositol-4,5-diphosphate 
(PIP2), which leads to accumulation of phosphatidylino-
sitol-3,4,5-triphosphate (PIP3). This secondary lipid mes-
senger recruits Akt to the cell membrane, where Akt is 
phosphorylated and regulates cellular processes by acti-
vating a number of substrates, such as the mammalian 
target of rapamycin (mTOR), BclxL/Bcl-2-associated 
death promoter (BAD), murine double minute (MDM2) 
and nuclear factor κB (NF-κB) [18, 19]. PI3K/Akt sign-
aling plays an important role in the events activated in 
response to angiogenic signals including basement mem-
brane remodeling, tip cell migration and stalk cell prolif-
eration [20–22]. Additionally, the activation of PI3K/Akt 
signaling can promote endothelial progenitor cell homing 
to ischemic tissue in the brain and heart, which is crucial 
for angiogenesis [23, 24].
Vascular endothelial growth factor (VEGF) is widely 
accepted as a primary inducer of angiogenesis [25]. Our 
previous results indicated that a VEGF/VEGFR mecha-
nism may be involved in in  vivo roxarsone-promoted 
angiogenesis [12]. Since PI3K/Akt activation mediates 
VEGF production and functions as a downstream signal 
of VEGF/VEGFR [26–28], the in  vivo inter-relationship 
between VEGF and the PI3K/Akt pathway is complex, 
and it would be interesting to examine if and how these 
factors play a role in arsenic-induced angiogenesis.
Jiaqiao et  al. [11] reported that roxarsone appeared 
to show the angiogenic potential in rat aorta endothe-
lial cells by cell proliferation assays and tube formation 
assays. Only two events of angiogenesis were focused 
on in their research, which may not fully investigate the 
roles of roxarsone on different periods. In this study, 
the role of PI3K/Akt signaling in roxarsone-induced 
angiogenesis in rat vascular endothelial cells (ECs) was 
firstly investigated by evaluating growth, survival, migra-
tion and tube formation in these cells. Zhang et al. [12] 
reported the promotion effect of roxarsone on growth 
of the MCF-7 xenograft tumors. As MCF-7 cells were 
oestrogen-responsive and may not be optimal for inves-
tigating the effects of roxarsone on tumor growth so that 
a xenograft model of B16–F10 cells in C57BL/6 mice was 
investigated to understand the potential carcinogenic or 
tumor-promoting risk of roxarsone.
Methods
Experimental animals and chemicals
Male Wistar rats (weighing  ~250  g) and C57BL/6 mice 
(weighing 20  ±  2  g) were obtained from the Center of 
Comparative Medicine, Yangzhou University, China. The 
animals were housed at 22 ±  2  °C and under 55 ±  5 % 
relative humidity with a regular 12-h light/dark schedule. 
Food and water were available ad libitum.
Roxarsone (Sigma-Aldrich, St. Louis, MO, USA) was 
dissolved in 5  mL methanol and then diluted to 50  mL 
with deionized water to obtain a 1.0 mM stock solution. 
The working solution of 0.01–10.0  µM roxarsone was 
made by further diluting the stock solution with incuba-
tion medium.
Sodium heparin and trypsin were purchased from 
Sigma-Aldrich. Dulbecco’s modified Eagle medium 
(DMEM), penicillin/streptomycin and fetal bovine 
serum (FBS) were purchased from Gibco (Invitrogen, 
Carlsbad, CA, USA). Recombinant rat VEGF165 was pur-
chased from Peprotech CO. (Rocky Hill, NJ, USA). The 
PI3K inhibitor LY294002 was from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Growth Factor Reduced 
Matrigel™ Matrix was purchased from BD Biosciences 
(San Jose, CA, USA). Rabbit monoclonal PI3K, phospho-
PI3K, Akt and phospho-Akt antibodies were from Cell 
Signaling Technology (Danvers, MA, USA). Rabbit poly-
clonal VEGF antibody, 5-bromo-2-deoxyUridine (BrdU) 
and mouse monoclonal BrdU antibody were purchased 
from Boster Biotechnology (Wuhan, China).
Isolation of rat thoracic aorta and primary EC culture
The Wistar rats were anaesthetized using 2 % thiopental 
sodium and sacrificed, and ECs were isolated from the 
thoracic aorta as described previously [11] and cultured 
in DMEM supplemented with 15 % (v/v) FBS, 100 µg/mL 
sodium heparin, 4  ng/mL VEGF and 100  U  penicillin/
streptomycin at 37 °C in a 5 % CO2 atmosphere. The cells 
were subcultured once they had formed a monolayer 
(after approximately 6 days of incubation). For the follow-
ing assays, the ECs were digested with 2 % trypsin, briefly 
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centrifuged at 1000 rpm for 10 min and resuspended at 
the required density in DMEM.
Cell survival assessment by the MTT assay
Cells were plated in reduced serum and growth factor-
containing DMEM (1:5 dilution of complete DMEM 
with non-supplemented DMEM) in 96-well plates at 
a cell density of 2 × 103 cells/well, and incubated over-
night. The wells were subsequently treated with PBS; 
5 ng/mL VEGF; 0.1, 1.0 or 10.0 µM roxarsone; 20.0 µM 
LY 294002 or 20.0  µM LY 294002 plus 1.0  µM roxar-
sone for 24  h. After incubation, MTT reduction assays 
were performed at a final concentration of 0.4  mg/mL 
in medium. After 4 h, reduced formazan was solubilized 
with 150  µL dimethyl sulphoxide (DMSO) by shaking 
for 10 min, and absorbance was measured at 570 nm in 
a microplate reader (Multiskan MS, Labsystems, USA). 
The optical density (OD) rate was calculated by dividing 
the OD value of the test compounds by the OD values of 
the PBS control to evaluate the changes in cell viability 
caused by treatment. Six wells were replicated for each 
treatment.
Cell proliferation assessment by the BrdU staining assay
Cells were seeded in 6-well plates at a cell density of 
1 ×  104  cells/well in reduced serum and growth factor-
containing DMEM and treated with the reagents as 
described above. After treatment for 24  h, BrdU was 
added at a final concentration of 30 µg/L in the medium, 
and incubated with the cells for 4 h. The cells were fixed 
with methanol containing 0.04 % H2O2 for 15 min; they 
were then incubated in 2 N hydrochloric acid at 37 °C for 
1  h. Subsequently, the cells were blocked in 5  % bovine 
serum albumin (BSA) for 20  min at room temperature, 
and were then incubated overnight with the BrdU anti-
body (1:200 dilution) at 4 °C. After the first antibody was 
washed off, the cells were incubated with goat anti-mouse 
IgG-FITC (1:50 dilution) for 30 min at room temperature 
lucifugally. This was followed by excitation at 494  nm, 
after which BrdU-positive cells were counted under the 
Leica DMI 400B fluorescence microscope under 200× 
magnification.
Cell migration assessment by the scratch assay
Cells were seeded in 6-well plates that were incubated 
in reduced serum and growth factor-containing DMEM 
till a monolayer was formed. The monolayer was then 
wounded by scratching with pipette tips and washed 
with PBS. The reagents described before were added to 
each well, and the wells were incubated at 37 °C in a 5 % 
CO2 atmosphere for 24  h. Cells were photographed at 
100× magnification under a light microscope, and the 
distances to which they had migrated were quantified by 
subtracting the width of the scratch at 0  h from that at 
24 h, measured by the Lecia QWin Pro V 3.5.1 software.
Matrigel‑induced tube formation assay
The Matrigel assay has been widely used for the in vitro 
measurement of tube formation of ECs and was per-
formed as described previously [11]. Each well of 96-well 
plates was coated with 50  µL Matrigel, and the plates 
were incubated at 37  °C for 6  h to allow the Matrigel 
to polymerize fully. Cells were seeded at a density of 
1.5  ×  103 per well into the prepared plates. Cells were 
treated as described before for 6 h. Images were acquired 
from five random fields of each well at a 200× magnifi-
cation and were photographed using a Lecia inverted 
phase-contrast microscope. Endothelial tube formation 
was evaluated during the period of incubation. Capillary-
like tube formation was quantified by counting the num-
ber of meshes in randomly selected images from each 
treatment group using Image-J with the Angiogenesis 
Analyze Plugin.
Mouse B16–F10 xenograft studies
B16–F10 melanoma cells were provided by the Research 
Group of Laboratory Animals of Yangzhou University, 
and maintained in DMEM containing 10 % FBS and peni-
cillin/streptomycin. Six-week-old C57BL/6 male mice 
weighing 20  g were housed at 22  ±  2  °C temperature, 
55 ±  5  % relative humidity with 12  h light/dark sched-
ule for 1 week of acclimatization. Then, 1 × 105 B16–F10 
cells in 0.3  mL nonsupplemented DMEM were injected 
subcutaneously into the external surface of the right ribs 
of the mice. The animals with visible tumors after cells 
injection 7 days, were intragastrically administered 0, 1, 
5 or 25  mg/kg roxarsone in 100  µL PBS once a day for 
1  week. During this week of administration, the body 
weight, feed and drink of the animals were assessed, 
and tumor measurement was conducted once a day. The 
length (L) and width (W) of tumors were measured using 
vernier calipers, and tumor volume was calculated using 
the formula L × W2. After the animals were sacrificed at 
1 week administration, the tumors were excised, weighed, 
fixed overnight in neutral buffered formalin, embedded 
in paraffin, and sectioned. The sections were then stained 
with hematoxylin–eosin (H&E) and photographed using 
a light microscope at 100× magnification.
Immunohistochemical staining for VEGF
Mouse tumor sections were de-paraffinized using tra-
ditional protocols and then incubated in 3  % peroxide 
for 10  min to inactivate endogenous peroxidase. Anti-
gen retrieval was accomplished in 0.1 M sodium citrate 
brought to a boil in a microwave oven at high power, and 
then heating was continued at 30  % power for 10  min. 
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Tissues were blocked with 5 % BSA, and incubated over-
night at 4  °C with antibodies against VEGF (1:100 dilu-
tion). Then, the tissues were incubated with secondary 
antibody conjugated to horseradish peroxidase, and 
AEC peroxidase substrate (Boster, Wuhan, China). Sec-
tions were then counterstained with Mayor’s hematoxy-
lin and photographed using a light microscope at 400× 
magnification.
Western blot analysis of PI3K/Akt signaling and VEGF 
expression
Treated cells and tumor tissues were lysed in RIPA lysis 
buffer with phenylmethyl sulfonylfluoride (PMSF) and 
a phosphatase inhibitor cocktail (Beyotime, Shanghai, 
China) on ice. Then, the lysates were subjected to SDS-
polyacrylamide gel electrophoresis with 20  µg protein 
loaded per lane. The gels were transferred to nitrocellu-
lose (NC) membranes using a Bio-Rad Transblot appa-
ratus. The membranes were blocked with 5  % BSA in 
TBS for 2  h at room temperature and then incubated 
overnight with the rabbit antibody against PI3K (1:1000 
dilution), phospho-PI3K (1:1000 dilution), Akt (1:1000 
dilution), phospho-Akt (1:1000 dilution), VEGF (1:200 
dilution) and β-actin (1:250 dilution). Blots were devel-
oped using the enhanced chemiluminescence (ECL) 
detection system (Bio-Rad Laboratories). The intensity of 
the blots was measured using Image-J.
Statistical analysis
The experiments were performed independently at least 
three times. The quantitative data are expressed as the 
mean ±  standard deviation. Statistical analysis was per-
formed using one-way analysis of variance (ANOVA) 
followed by the Bonferroni post-test unless otherwise 
noted, and p < 0.05 was considered to indicate statistical 
significance.
Results
Roxarsone stimulates EC survival, proliferation, migration 
and angiogenesis
When ECs were incubated with 1.0  µM roxarsone and 
VEGF, the relative OD rate was significantly higher than 
that of the PBS control, as determined by the MTT assay 
(Fig. 1). The effect of roxarsone on EC proliferation was 
also determined by BrdU staining (Fig.  2). Treatment 
with 1.0  µM roxarsone and VEGF led to a significant 
increase in cell proliferation compared with the control 
cells. The scratch assay (Fig. 3) was performed to evaluate 
the impact of roxarsone on cell migration. The distance 
that the cells treated with 1.0 µM roxarsone had migrated 
was significantly longer than that travelled by the cells 
treated with the PBS control, and similar to that migra-
tion length of cells treated with VEGF.
We next examined in  vitro angiogenesis following 
stimulation of ECs with the reagents described before in 
Matrigel plates (Fig.  4). The results revealed that treat-
ment with 1.0  µM roxarsone and VEGF significantly 
stimulated in vitro angiogenesis in ECs. However, treat-
ment with 0.1 and 10.0 µM roxarsone did not have a sta-
tistically significant effect on any angiogenic parameters. 
Further, treatment with LY294002, a PI3K inhibitor, 
resulted in a significant reduction in vascular endothe-
lial cell vitality, the number of BrdU-positive cells, the 
migration distance and the number of meshes in the tube 
formation assay. Treatment with LY294002 combined 
with 1.0  µM roxarsone led to a significant decrease in 
the angiogenic parameters compared to treatment with 
1.0 µmol/L roxarsone alone.
The PI3K/Akt/VEGF cascade is stimulated by roxarsone 
in ECs
Since activation of PI3K/Akt is an important signaling 
event for angiogenesis, we examined whether roxarsone 
regulates phosphorylation of PI3K and Akt in ECs. We 
found that treatment with VEGF and 1.0 µM roxarsone 
significantly increased phosphorylation of PI3K and Akt 
(Fig.  5A) as well as VEGF expression (Fig.  5B). Further, 
LY294002 was found to suppress PI3K and Akt phospho-
rylation via its effect on VEGF expression. Phosphoryla-
tion of PI3K and Akt and the expression of VEGF in ECs 
treated with LY294002 plus 1.0 µM roxarsone were sig-
nificantly lower than that in ECs treated with 1.0 µM rox-
arsone. These results suggest that the PI3K/Akt signaling 
pathway may be stimulated by roxarsone and required for 
roxarsone-induced VEGF expression in ECs.
Fig. 1 The effects of different treatments on the vitality of endothe-
lial cells (ECs). The MTT assay was performed to evaluate the vitality 
of ECs treated with the indicated reagents for 24 h. The results pre-
sented are the mean ± SD values of three independent experiments 
relative to the PBS control. *p < 0.05 vs. the PBS control; ##p < 0.01 vs. 
1.0 µM roxarsone
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Roxarsone promotes the growth of mouse B16–F10 
xenografts
From the day of intragastric administration of 0, 1, 5 
or 25  mg/kg roxarsone, the body weights of the mice 
changed, decreasing first and then increasing, but there 
was no significant difference between treatment groups 
(data not shown). Additionally, none of the mice showed 
any abnormal nervous symptoms. Surface measure-
ment indicated that tumor growth occurred in all of the 
mice in the study, regardless of which treatment group 
they belonged to (Fig.  6A). However, mice that received 
25 mg/kg of roxarsone had significantly heavier (Fig. 6B) 
and larger tumors than the untreated mice. Mice treated 
with 5  mg/kg roxarsone also had heavier and larger 
tumors, but the difference was not significant compared 
to the untreated group. Staining of paraffin sections of 
2-week-old tumors stained with H&E (Fig.  7) indicated 
that there were changes in the growth pattern of tumor 
cells and blood vessel size, according to the roxarsone 
dose administered. As seen in Fig. 7, the B16–F10 cells in 
the xenograft tumors of untreated mice were typically dif-
fuse, without a distinct growth pattern. The structure and 
organization of the xenograft tumors in the 5 and 25 mg/
kg roxarsone groups appeared tight, and the B16–F10 
cells showed inward cluster growth that was centered on 
a blood vessel. In contrast, the structure of the xenograft 
tumors of mice treated with 1 mg/kg roxarsone was simi-
lar to that of untreated mice. Additionally, the xenografts 
in mice administered 5 and 25 mg/kg roxarsone contained 
a high number of vessels and vessels of a larger diameter.
Fig. 2 The effects of different treatments on the proliferation of endothelial cells (ECs). A The ECs treated with the indicated reagents for 24 h were 
subjected to BrdU staining (×200), and the number of positive ECs from at least five random fields per group were counted. Representative images 
are shown for the a PBS control; b VEGF; c–e 0.1, 1.0 and 10.0 µM roxarsone; f LY294002 and g LY294002 plus 1.0 µM roxarsone groups. B The number 
of positive cells are presented as the mean ± SD values from three independent experiments. *p < 0.05, **p < 0.01 vs. the PBS control; ##p < 0.01 vs. 
1.0 µM roxarsone
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Roxarsone induces activation of PI3K/Akt signaling 
and VEGF expression
Recent evidence has indicated that the dysregulation of 
PI3K signaling promotes tumorigenesis and angiogenesis 
in various cancer types [18, 19, 29]. Therefore, in the pre-
sent study, phosphorylation of PI3K/Akt signaling in the 
B16–F10 xenografts of mice that were administered roxar-
sone was examined using western blot analysis. We found 
that treatment with 25 mg/kg roxarsone resulted in a sig-
nificant increase in phosphorylation of PI3K and Akt when 
compared with untreated mice (Fig. 8A). Similarly, expres-
sion of VEGF, an index related to clinical outcome in can-
cer patients [24], in the B16–F10 xenografts of mice that 
were administered 25  mg/kg roxarsone was significantly 
higher than that of untreated mice; this was also observed 
in our western blot results (Fig. 8B). Immunohistochemi-
cal analysis of VEGF demonstrated that the xenografts in 
untreated and 1 mg/kg roxarsone-treated mice contained 
a low number of vessels surrounded by positive staining, 
whereas the xenografts in the 5 and 25 mg/kg roxarsone 
groups contained a greater number of vessels (Fig. 8C).
Discussion
In this study, we used rat endothelial cells and a B16–F10 
xenograft model to determine (1) whether exposure to 
roxarsone induces angiogenesis, (2) whether PI3K/Akt 
Fig. 3 The effects of different treatments on the migration ability of endothelial cells (ECs). A ECs were wounded with a pipette and treated 
with the indicated reagents for 24 h. Representative images (×100) are shown for the a PBS control; b VEGF; c–e 0.1, 1.0 and 10.0 µM roxarsone, f 
LY294002 and g LY294002 plus 1.0 µM roxarsone groups. B The distance that the cells had migrated was calculated by subtracting the width of the 
scratch at 0 h from the width at 24 h. The results represent the mean ± SD values from three independent experiments. *p < 0.05, **p < 0.01 vs. the 
PBS control; ##p < 0.01 vs. 1.0 µM roxarsone
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signaling is involved in roxarsone-induced angiogenesis, 
and (3) whether roxarsone promotes tumor growth.
Vessel sprouting (angiogenesis) is an extensively stud-
ied aspect of vascularization. Upon activation of ECs by 
proangiogenic molecules, cell–cell junctions and the 
basement membrane are remodeled in tandem with 
pericyte detachment, which allows tip cells to migrate in 
response to signals. The sprout then elongates through 
the proliferation of stalk cells, which form a lumen and 
recruit pericytes for stabilization [29]. In a previous 
MTT assay or tube formation assay, roxarsone showed 
a non dose-depended effect on angiogenesis [11, 12], 
which appeared to have peak value of stimulating effects 
at 1  µM levels and slightly decreased in the stimulating 
effects at high levels (1–10 µM). The data presented here 
suggest that roxarsone not only increased EC vitality 
(Fig. 1) and promoted tube formation in Matrigel (Fig. 4), 
but also enhanced EC proliferation (Fig.  2) and migra-
tion (Fig. 3), based on the findings of the BrdU assay and 
scratch assay respectively. These are rarely reported but 
Fig. 4 The effects of different treatments on endothelial cell (EC) tube formation. A After treatment with the indicated reagents for 6 h, tubular 
structure in each group was photographed at ×200 magnification. Representative images are shown for the a PBS control; b VEGF; c–e 0.1, 1.0 and 
10.0 µM roxarsone, f LY294002 and g LY294002 plus 1.0 µM roxarsone groups. B The number of meshes in five randomly selected images for each 
group was measured using Image-J with the Angiogenesis Analysis Plugin. The results represent the mean ± SD values from three independent 
experiments. *p < 0.05, **p < 0.01 vs. the PBS control; ##p < 0.01 vs. 1.0 µM roxarsone
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Fig. 5 The effects of different treatments on activation of PI3K/Akt and expression of VEGF. Western blotting of total cell lysates treated with the 
indicated reagents for 1 h was performed, and β-actin was used as a loading PBS control. A The levels of PI3K and Akt phosphorylation were deter-
mined by phosphorylated proteins standardized to non-phosphorylated proteins. B The VEGF level of the cell lysates was determined by standard-
izing VEGF expression to β-actin expression. The results represent the mean ± SD values from three independent experiments. *p < 0.05, **p < 0.01 
vs. the PBS control; ##p < 0.01 vs. 1.0 µM roxarsone
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not trivial events associated with angiogenesis. Addi-
tionally, the effects of roxarsone were concentration 
dependent and observed in the concentration range of 
0.01–1.0 µM. Although no obvious inhibitory effect was 
observed when 10.0 µM of roxarsone was used, the pro-
angiogenic effect was indeed weakened at this concen-
tration. It was without a doubt that the dosage range we 
used here was narrow while interval was broad, which 
limited the precise investigation in dose-effect relation-
ship of roxarsone.
PI3K/Akt signaling is involved in multiple signaling 
pathways in the regulation of cell proliferation, differ-
entiation, survival and migration [30], and it is closely 
associated with the occurrence and development of angi-
ogenesis. To determine whether PI3K/Akt signaling was 
required for the effects of roxarsone on ECs, we assessed 
PI3K/Akt signaling by western blot analysis. The results 
indicated that roxarsone indeed triggered phosphoryla-
tion of PI3K and Akt (Fig.  5A). Further, incubation of 
ECs with the PI3K inhibitor LY294002 abrogated acti-
vation of ECs induced by roxarsone via decrease in the 
phosphorylation of PI3K and Akt. These findings indi-
cate that activation of PI3K/Akt signaling is required for 
roxarsone-induced angiogenesis. In the present study, 
we also found that roxarsone induced an increase in the 
expression of VEGF (Fig. 5B), which is a key factor in the 
induction of angiogenesis. Inhibition of PI3K/Akt signal-
ing abrogated the increase in VEGF expression induced 
by roxarsone, which suggests that roxarsone triggered the 
PI3K/Akt/VEGF signaling cascade. Our current results 
are consistent with previous reports [31, 32]. However, 
we did not examine how PI3K/Akt signaling triggered 
by roxarsone regulates VEGF expression. Wang et  al. 
[33] showed that arsenic increased HIF-1α expression 
through PI3K/Akt signaling to induce VEGF expression 
in an oxygen-independent manner in human uroepi-
thelial cells. Additionally, Tsai et  al. [34] demonstrated 
that inhibitor of DNA binding 1 (Id1) was involved in 
the arsenic-promoted angiogenesis via PI3K/Akt/NF-κB 
signaling. Arsenite treatment decreased the activity of 
GSK3 [35], and also played the role of a downstream 
effector of PI3K/Akt, which caused β-catenin accumula-
tion in the nucleus and VEGF expression [36]. Interest-
ingly, Wang et  al. [37] reported that arsenic exposure 
activated PI3K/Akt signaling to induce GSK3 phospho-
rylation in DLD-1 and HLT116 cells, while Piyajit et  al. 
[35] demonstrated that arsenite inhibited the activity of 
GSK3 without activating its upstream kinase Akt. Thus, 
some of the findings reported in the literature so far are 
controversial. Given that the mechanism for arsenic-
induced promotion of VEGF expression through PI3K/
Akt signaling is complicated, the mechanisms underlying 
the effects of roxarsone remain to be investigated in the 
future.
For many years, arsenic has been related to various 
types of cancer, but there is very little evidence for the 
direct carcinogenic effect of arsenic [38, 39]. Instead, 
the tumor-promoting effect of arsenic appears to be 
enhanced in the presence of other carcinogens such 
as UV radiation [40]. In fact, the present and previous 
Fig. 6 Roxarsone promotes the growth of B16–F10 xenografts growth. B16–F10 tumor cells (1 × 105) were implanted subcutaneously into the 
external surface of the right ribs of mice. After 7 days, the mice were intragastrically administered 0, 1, 5 or 25 mg/kg roxarsone once a day for 
another 7 days; the corresponding groups are designed as the Control, Low Rox, Middle Rox and High Rox groups respectively. A Tumor size was 
measured using vernier calipers, and tumor volume was calculated as described in “Methods” section. Data represent the average tumor volumes 
at the given day after implantation. Significant growth was observed in all the groups (p < 0.05, n = 6), and significant differences were observed 
between treatment groups and the PBS control group (*p < 0.05, as determined by two-way ANOVA). B B16–F10 xenografts were excised and 
weighed. The results represent the mean ± SD values of six mice. *p < 0.05, **p < 0.01 vs. the PBS control
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research on the B16–F10 xenograft model and the MCF-7 
xenograft model [12] has only provided evidence for the 
tumor-enhancing effect of roxarsone when it is present as 
a co-carcinogen. Nicole et al. [8] demonstrated that sig-
nificant tumor growth was observed in all animals that 
were given biweekly injections of 0.5–5.0 mg/kg As(III), 
with the largest tumors occurring in animals treated with 
lower doses of As(III). The present results indicate that 
25 mg/kg roxarsone, a far higher dose than that used in 
the Nicole et  al. study, significantly enhanced B16–F10 
xenograft growth (Fig. 6). The similarity in the effects of 
these arsenic compounds even though they were admin-
istered at different dosages may be related to differences 
in the mode of administration: that is, intraperitoneal 
administration may be associated with higher plasma 
concentration and longer maintenance time than oral 
administration [41].
In the present study, the H&E staining (Fig.  7) and 
VEGF immunohistochemical staining (Fig.  8C) results 
indicated that roxarsone was capable of inducing tumor 
Fig. 7 Roxarsone affects the growth pattern of B16–F10 xenografts. The xenograft tumors were excised; paraffin sections were created and stained 
with H&E staining and histologically analyzed (×100). Representative images (of at least five mice per group) are shown for the A PBS control and 
B–D 1, 5, and 25 mg/kg roxarsone groups designed as Control, Low Rox, Middle Rox and High Rox. Clustered growth with centrally located blood 
vessels (indicated by the arrow) was observed in the roxarsone groups, but this was rarely observed in the PBS control group
(See figure on next page.) 
Fig. 8 Roxarsone promotes activation of PI3K/Akt and expression of VEGF in B16–F10 xenografts. Western blotting of total tumor lysates was 
performed with β-actin used as a loading PBS control. The groups designed as Control, Low Rox, Middle Rox and High Rox represent the mice that 
were administered 0, 1, 5 and 25 mg/kg roxarsone respectively. A The levels of PI3K and Akt phosphorylation were determined by phosphorylated 
proteins standardized to non-phosphorylated proteins. B The VEGF level of tumors was determined by VEGF expression standardized to β-actin 
expression. The results represent the mean ± SD values from three independent experiments. *p < 0.05 vs. the PBS control. C The xenograft tumors 
were excised, and paraffin sections were subjected to VEGF immunochemical analysis (×400). Representative images (of at least five mice per 
group) are shown for the a PBS control and b–d 1, 5 and 25 mg/kg roxarsone groups. Blood vessels surrounding the positive staining regions (arrow 
indicated) were observed in the PBS control and roxarsone groups
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angiogenesis, which is an important process in the devel-
opment of most tumors and might further explain the 
co-carcinogenicity of roxarsone. IHC analysis of VEGF in 
tumors might be a feasible method for assessing angio-
genesis when the blood vessels of tumors are immature 
with the intact lumen of ECs invisible in H&E staining.
Vasculogenic mimicry (VM), which was observed in 
melanomas by Maniotis [42], has been widely recog-
nized as a novel indicator of tumor microcirculation 
[43, 44]. The mechanism of VM may be attributed to 
tumor cell transformation and matrix remodeling [45]. 
Notably, VEGF has an impact on the formation of VM, 
and cells with high expression of VEGF appear to have 
the potential to form VM [46, 47]. The relative expres-
sion of VEGF in xenografts as measured via western blot 
analysis (Fig. 8B) also indicated that high levels of VEGF 
expression were closely associated with the growth of 
xenografts, in which microcirculation was more obvious 
(Figs. 7, 8C) in mice exposed to high doses of roxarsone.
Recent studies have highlighted the importance of the 
PI3K/Akt axis in various types of tumor cells. PI3K/Akt 
signaling is implicated in different processes that are 
characteristic of cancer including growth signal auton-
omy, insensitivity to antiproliferation signals, inhibition 
of apoptosis, angiogenesis, invasion and metastasis [48]. 
In the current study, western blot analysis of B16–F10 
xenografts showed that the phosphorylation level of 
PI3K/Akt increased with the dose of roxarsone adminis-
tered (Fig. 8A). Although these data are still preliminary 
and need to be confirmed in more detailed experiments, 
they nonetheless demonstrate that a PI3K/Akt mecha-
nism may be involved in the development of B16–F10 
xenografts induced by roxarsone.
Conclusions
Altogether, our findings suggest that roxarsone promoted 
EC vitality, proliferation, migration and tube formation 
in  vitro and B16–F10 xenograft growth with pro-angi-
ogenic potential in  vivo. Importantly, PI3K/Akt signal-
ing played a role in the roxarsone-induced angiogenesis. 
Thus, understanding the angiogenic impact of roxarsone 
and its mechanism would shed light on the potential 
safety and risks of using arsenic compounds in human 
beings.
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